Uppsala, Sweden, 2011-01-18 08:18 CET (GLOBE NEWSWIRE) -- Oasmia Pharmaceutical AB has applied for a listing on the General Standard at Frankfurt Stock Exchange (DAX) from Monday, January 24, 2011. The decision will be announced on Friday, January 21. If the application is approved, Oasmia will be the first Swedish company to be listed on the regulated German market. The investment bank Silvia Quandt & Cie. AG is co-applicant in the listing process.
- We are glad to participate in one of the largest stock markets in the world. Our products are meant to be sold worldwide and in this way, we can reach a much larger group of international investors who have expressed interest in the company, says Julian Aleksov, CEO of Oasmia Pharmaceutical AB.
Oasmia is currently listed on NASDAQ OMX Stockholm stock exchange and Carnegie Investment Bank is financial advisor. A listing at Frankfurt Stock Exchange will be a dual listing.
About Oasmia
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company was registered in 1999 and is located in Uppsala, Sweden.
Disclaimer
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of Oasmia's securities. Specifically, the risks and uncertainties that could affect the development of Paccal® Vet include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with Paccal® Vet in particular, including, without limitation, the potential for Paccal® Vet to be proved safe and effective (or to achieve response rates) for the treatment of the indications noted in this press release or any other indication, determinations by regulatory, patent and administrative governmental authorities, the potential that Paccal® Vet will not produce high rates of complete remission in patients with mastocytoma, the possibility that the registration trial for Paccal® Vet as a treatment for mastocytoma in dogs will not occur, the possibility that the U.S. Food and Drug Administration will not approve a phase III registration strategy for Paccal® Vet if proposed by Oasmia, the potential that Abbott will not exercise its distribution rights, Oasmia's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, and costs of developing, producing and supplying Paccal® Vet. Except as may be required by law, Oasmia does not intend to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. Information is also available at nasdaqomxnordic.com and oasmia.com
